List of Excipients in Branded Drug ELMIRON

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	ALUMINUM OXIDE
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	BUTYL ALCOHOL
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	CELLULOSE, MICROCRYSTALLINE
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	D&C YELLOW NO. 10
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	FD&C BLUE NO. 1
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	FD&C BLUE NO. 2
Janssen Pharmaceuticals Inc	ELMIRON	pentosan polysulfate sodium	50458-098	FD&C RED NO. 40

Last updated: August 4, 2026

ELMIRON's commercial opportunity is concentrated in excipient-led differentiation rather than new chemical-entity protection. The product is an immediate-release 100 mg pentosan polysulfate sodium capsule for interstitial cystitis. Its current formulation uses conventional tablet and capsule excipients, creating potential opportunities in liquid delivery, modified release, lower-swallow-burden formats, impurity control, and patient-friendly packaging. Generic competition remains the principal price risk because the active ingredient is an established oral drug with limited formulation complexity.

ELMIRON Excipient Strategy and Commercial Opportunities

What is ELMIRON and how does its formulation work?

ELMIRON is the U.S. brand name for pentosan polysulfate sodium, an orally administered, weakly anticoagulant polysaccharide approved for relief of bladder pain or discomfort associated with interstitial cystitis. The labeled dose is 100 mg three times daily, taken at least one hour before meals or two hours after meals.[1]

Pentosan polysulfate sodium is not a conventional small-molecule API. It is a sulfated semisynthetic polysaccharide with variable molecular characteristics and low oral bioavailability. The formulation therefore depends on consistent particle properties, capsule fill uniformity, dissolution behavior, and control of chemical and biological impurities.

Attribute	ELMIRON profile
Active ingredient	Pentosan polysulfate sodium
Dosage form	Oral hard gelatin capsule
Strength	100 mg
Labeled schedule	Three times daily
FDA indication	Interstitial cystitis
Route	Oral
Release type	Immediate release
Manufacturer/label holder	Janssen Pharmaceuticals, Inc.
Key administration condition	Taken on an empty stomach
Principal commercial issue	Chronic use with high cumulative capsule burden

The empty-stomach requirement is commercially relevant. Patients must coordinate three daily doses with meals, while long-term treatment can require thousands of capsules. A formulation that improves adherence without changing exposure could have value even if it does not materially improve clinical efficacy.

What excipients are used in ELMIRON capsules?

The ELMIRON label identifies a conventional excipient system that supports capsule manufacture, powder flow, capsule integrity, color, and finished-product stability.[1,2]

Excipient or component	Likely formulation function
Dibasic calcium phosphate	Diluent and powder-flow aid
Microcrystalline cellulose	Diluent, structural aid, and flow modifier
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting or dispersion aid
Talc	Glidant and anti-adherent
Carnauba wax	Capsule or surface-processing component
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and color modifier
FD&C Red No. 40	Capsule colorant

The formulation is commercially conventional. That reduces manufacturing risk but also limits the ability to obtain durable differentiation from the existing excipient combination alone. A generic manufacturer could generally pursue the same immediate-release dosage form with a different inactive-ingredient system, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and suitability of the excipients.

Which excipient attributes matter most for pentosan polysulfate sodium?

The highest-value formulation controls are likely to be:

1. Powder flow and blend uniformity. The 100 mg fill is relatively small compared with the total capsule mass, so segregation and content-uniformity controls are important.
2. Moisture control. Polysaccharide materials can be sensitive to moisture-related changes in flow, viscosity, and chemical stability.
3. Dissolution and wetting. Sodium lauryl sulfate or another wetting strategy can help manage dispersion of a charged, polymeric material.
4. Lubricant control. Excess magnesium stearate can reduce wetting and slow dissolution.
5. Molecular-weight distribution and impurity profile. These are API controls rather than conventional excipient controls, but they are central to product consistency.
6. Capsule-shell compatibility. Gelatin moisture content, brittleness, color migration, and storage performance affect commercial quality.

The most defensible technical strategy is to treat the product as a polymeric API with a controlled solid-state and impurity profile, rather than as a simple low-dose powder capsule.

What formulation patents protect ELMIRON?

The original ELMIRON commercial position was based primarily on the approved active ingredient and its use in interstitial cystitis, not on a highly complex delivery platform. The core formulation uses widely available excipients and an immediate-release hard capsule.

Public FDA resources should be used to verify any current Orange Book-listed patents before an investment or launch decision. Historic composition-of-matter and use protections associated with pentosan polysulfate sodium are old relative to the 1986 approval date and are unlikely to provide a meaningful current barrier to an otherwise compliant generic capsule.[1,3]

Protection category	Commercial relevance
Active ingredient protection	Historic protection; unlikely to be the main current barrier
Interstitial-cystitis method of use	Must be reviewed for any remaining enforceable claims
Immediate-release capsule formulation	Limited strength because excipients are conventional
Manufacturing process	Potentially relevant if claims cover API quality, impurity removal, or specific process controls
New dosage form or delivery system	Main opportunity for later-life exclusivity
Trade secrets	Potentially important for polymer characterization, process control, and scale-up

A reformulated product would need claims directed to a specific formulation, dosage form, manufacturing process, or clinical use. Broad claims covering ordinary fillers, lubricants, and capsule-shell materials would face substantial validity and obviousness pressure.

What is the Orange Book status of ELMIRON?

ELMIRON is associated with FDA New Drug Application 020193. The Orange Book remains the principal U.S. source for listed patents and regulatory exclusivity associated with the reference product.[3]

The commercial assessment is straightforward:

• ELMIRON is an established small-molecule-like oral drug product from an abbreviated application perspective, even though pentosan polysulfate sodium is polymeric in nature.
• Generic applicants can evaluate an ANDA pathway for a capsule product if FDA's bioequivalence and pharmaceutical-equivalence requirements can be met.
• A new excipient or altered excipient level does not independently create exclusivity.
• A novel delivery system may require a 505(b)(2) application rather than a conventional ANDA, depending on the extent of the formulation and clinical changes.
• Any current patent listed for ELMIRON must be checked in the active Orange Book edition and paired with the underlying patent and litigation record.

When does ELMIRON lose exclusivity?

The main commercial exclusivity associated with ELMIRON has already elapsed. The product was approved in 1986, so the five-year NCE exclusivity period and the principal historical patent term are no longer the relevant barriers to entry.[1,3]

Current protection is more likely to depend on:

• Any remaining listed method-of-use patents.
• Later-added patents covering a specific formulation or delivery system.
• Regulatory exclusivity associated with a genuinely new product, if granted.
• Manufacturing know-how that is difficult to reproduce but not independently enforceable as a patent.

Which excipient strategies could create commercial value?

1. Lower-burden dosing formats

The three-times-daily regimen creates a clear adherence problem. A modified-release capsule could provide the strongest commercial differentiation if it preserves exposure, tolerability, and the clinical effect required for interstitial cystitis.

Potential platforms include:

• Hydrophilic matrix systems using hypromellose or similar polymers.
• Multiparticulate pellets in a capsule.
• Enteric-coated particles.
• Osmotic or diffusion-controlled systems.
• Higher-strength capsules that reduce capsule count, subject to dose proportionality and safety.

A modified-release product would likely require new pharmacokinetic and clinical support. It would not be a simple generic substitution.

2. Liquid or dispersible formulations

A liquid, suspension, or dispersible dosage form could address patients who have difficulty swallowing capsules. The primary technical risks are:

• Polymer settling and redispersion.
• Viscosity changes during storage.
• Chemical degradation in aqueous media.
• Microbial control.
• Taste and mouthfeel.
• Dose-measurement accuracy.
• Compatibility with preservatives and container-closure systems.

A dry powder for reconstitution may be more practical than a ready-to-use liquid because it reduces water-driven stability risk. Sachets, unit-dose packets, or oral-dispersible granules could support specialty-pharmacy distribution.

3. Reduced excipient and allergen burden

A simplified capsule could remove or reduce excipients that generate patient, regulatory, or supply-chain concerns. Potential targets include:

• Colorant-free capsules.
• Titanium-dioxide-free shells.
• Sodium-lauryl-sulfate-free formulations.
• Plant-based or hypromellose capsule shells.
• Lower-lubricant systems.
• Direct-compression or dry-granulation processes with fewer processing aids.

This strategy is unlikely to justify a high premium by itself. It is more useful as a procurement, quality, or patient-preference differentiator.

4. Stability and packaging improvements

Pentosan polysulfate sodium products may benefit from packaging engineered around moisture control and dose compliance. Commercial options include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Calendarized three-dose packaging.
• Unit-dose specialty-pharmacy packs.
• Electronic adherence packaging.

Packaging patents may offer narrower but practical protection, particularly when tied to stability data, dosing schedules, or specialty-pharmacy workflows.

5. Pediatric and geriatric delivery

Interstitial cystitis is primarily an adult condition, but swallowability remains relevant for older patients and individuals with dysphagia. A sprinkle capsule, granule, or oral suspension could expand use in selected populations. The formulation would need evidence that administration with permitted soft foods does not alter dose delivery or exposure.

How strong is the ELMIRON patent estate?

The legacy patent estate is weaker than that of a recently approved drug because the product has been marketed for decades and uses a conventional capsule platform. The strongest potential barriers are not ordinary excipient claims. They are likely to involve:

• Specific controlled-release architecture.
• Defined pentosan polysulfate molecular characteristics.
• Purity or impurity specifications linked to clinical performance.
• New dosing regimens.
• Combination products.
• Specialized manufacturing steps.
• Patient populations or biomarker-defined use.

Patent strategy	Likely strength	Commercial assessment
Generic capsule with conventional excipients	Low	Main source of price competition
Colorant-free or vegetarian capsule	Low to moderate	Useful differentiation, limited exclusivity
New controlled-release dosage form	Moderate to high	Stronger 505(b)(2) opportunity if clinically validated
Liquid or reconstitutable formulation	Moderate	Technical execution and stability determine value
API impurity-control process	Moderate	Can create manufacturing friction if claims are narrow and valid
New method of use	Variable	Depends on clinical evidence and claim scope
Adherence-oriented packaging	Low to moderate	Commercially useful but usually narrow

What generic entry risks exist for ELMIRON?

Generic entry risk is meaningful because the reference product has an established dosage form and no obvious dependence on a complex device or biologic manufacturing process.

Paragraph IV challenges

An ANDA applicant could use a Paragraph IV certification against any listed patent that it considers invalid, unenforceable, or not infringed. The first substantially complete Paragraph IV ANDA may qualify for 180-day generic exclusivity under the Hatch-Waxman framework, subject to statutory conditions.[4]

The likely challenge points would include:

• Whether a method-of-use patent is properly listed.
• Whether the proposed label carves out the patented indication or dosing instruction.
• Whether formulation differences affect bioequivalence.
• Whether any listed patent claims a product feature actually present in the generic product.
• Whether a process patent can be avoided through an alternative manufacturing route.

Generic launch scenarios

Scenario	Market effect
One approved generic capsule	Moderate price erosion; brand may retain specialty prescribers
Several generic capsule entrants	Rapid price compression and pharmacy substitution
Authorized generic	Greater brand control but potentially lower-margin channel sales
505(b)(2) modified-release product	Differentiated pricing with added development risk
Liquid or sprinkle product	Niche uptake and possible specialty positioning
Manufacturing disruption at a generic supplier	Temporary supply advantage for other manufacturers

A generic capsule would likely compete primarily on price, availability, wholesaler coverage, and payer substitution. Excipient differences would rarely influence prescribing unless they affect tolerability, allergen restrictions, or capsule suitability.

Which companies are positioned to challenge ELMIRON?

The most probable challengers are established generic manufacturers with experience in oral capsules and products requiring polymer characterization. Potential categories include:

• Large multi-product ANDA manufacturers.
• Specialty generic companies focused on urology.
• Contract development and manufacturing organizations with capsule and multiparticulate capabilities.
• 505(b)(2) developers pursuing modified-release or liquid delivery.
• Regional manufacturers seeking supply in Canada, Europe, or other markets.

A credible challenger needs more than capsule-filling capacity. It needs analytical methods for a polymeric API, robust dissolution testing, impurity characterization, and a bioequivalence strategy that FDA will accept for a low-bioavailability product.

What manufacturing and IP barriers affect commercial entry?

The main operational barrier is reproducibility. Pentosan polysulfate sodium can present greater analytical complexity than a conventional crystalline small molecule. Commercially relevant controls include:

• Molecular-weight distribution.
• Degree and pattern of sulfation.
• Residual reagents and degradation products.
• Counterion composition.
• Moisture and bulk density.
• Particle-size distribution.
• Dissolution across pH conditions.
• Capsule-fill uniformity.
• Extractables and leachables from packaging.

These controls may create practical barriers without producing broad patent exclusivity. A supplier with validated analytical methods and a stable API source could have an advantage over a low-cost entrant.

How does ELMIRON compare with other interstitial-cystitis products?

ELMIRON occupies a distinctive position as the principal oral prescription product specifically approved for interstitial cystitis. Competing management approaches include analgesics, antihistamines, tricyclic antidepressants, bladder instillations, pelvic-floor therapy, and procedural interventions. Many are not direct substitutes in FDA labeling or mechanism.

Product or approach	Dosage-form opportunity	Competitive relationship
ELMIRON capsule	Immediate-release oral capsule	Reference product
Generic pentosan polysulfate sodium	Capsule	Direct price competition
Reformulated pentosan polysulfate	Modified release, liquid, or sprinkle	Direct but differentiated competition
Bladder instillation products	Local administration	Clinical alternative, not direct generic substitution
Oral symptom-control medicines	Tablets or capsules	Adjacent symptomatic competition
Nonpharmacologic therapy	Procedure or behavioral intervention	Indirect competition

The best commercial white space is a delivery product that reduces administration friction while retaining the existing prescriber and patient base.

What is the revenue exposure for ELMIRON?

Public FDA sources establish approval, labeling, and regulatory status but do not establish current net sales. Revenue exposure depends on branded demand, generic entry timing, payer substitution, prescription volume, and the share of patients receiving long-term therapy.

The economic sensitivity is highest for:

• Duration of generic exclusivity or market protection.
• Number of generic entrants.
• Brand retention among urologists.
• Net price after rebates.
• Patient persistence over multiple years.
• Availability of a differentiated successor product.

A successful modified-release or patient-friendly formulation could protect value better than a minor excipient substitution. A colorant-free or vegetarian capsule would improve product positioning but would probably produce limited revenue protection without clinical or adherence evidence.

What is the FDA regulatory path for new ELMIRON formulations?

A conventional capsule intended to match ELMIRON would generally be evaluated through an ANDA if the product meets FDA requirements for sameness and bioequivalence. A formulation with a new route, release profile, indication, strength, or clinical use may require a 505(b)(2) application.[5]

Product concept	Likely U.S. pathway
Conventional immediate-release capsule	ANDA
Same capsule with different inactive ingredients	Usually ANDA, subject to suitability and bioequivalence
Higher-strength capsule	ANDA or 505(b)(2), depending on sameness and evidence
Modified-release capsule	Usually 505(b)(2) unless FDA determines ANDA suitability
Oral liquid or suspension	Often 505(b)(2), depending on reference-product relationship
New indication or regimen	505(b)(2) or supplemental NDA
New combination product	505(b)(2) or NDA

A new excipient may require additional safety justification, especially if used at a novel route, concentration, or exposure level. FDA's inactive-ingredient database can support precedent analysis but does not eliminate formulation-specific regulatory requirements.[6]

Key Takeaways

• ELMIRON is a 100 mg immediate-release pentosan polysulfate sodium capsule taken three times daily.
• Its excipient system is conventional and does not create a strong standalone barrier to generic competition.
• The largest technical opportunity is a modified-release or lower-burden delivery system.
• Liquid, sprinkle, dry-powder, colorant-free, and vegetarian-capsule formats offer secondary differentiation opportunities.
• Generic entry risk is substantial because the product is old, orally administered, and not dependent on biologic manufacturing.
• The strongest potential IP would cover release architecture, API quality attributes, manufacturing controls, or a clinically supported new regimen.
• FDA pathway selection will determine development cost: ANDA for a qualifying equivalent capsule, 505(b)(2) for meaningful formulation or clinical changes.
• Public regulatory sources do not establish current ELMIRON net sales; commercial exposure must be modeled around generic entry, persistence, payer substitution, and product differentiation.

FAQs

Can ELMIRON be reformulated without changing the active ingredient?

Yes. A developer can change excipients, capsule-shell materials, packaging, or release technology, but the regulatory pathway depends on whether the product remains pharmaceutically equivalent and bioequivalent to the reference product.

Could a once-daily ELMIRON product obtain new exclusivity?

Potentially. A once-daily product with a novel release profile and supporting clinical or pharmacokinetic evidence could qualify for protection tied to the formulation, regimen, or approved product. Excipients alone would not guarantee exclusivity.

Are excipient differences enough to block generic substitution?

Usually not. Different inactive ingredients may be permissible if the generic meets FDA requirements and the excipients are suitable for the dosage form and route.

Would a liquid ELMIRON product improve market access?

It could address swallowing difficulty and selected adherence problems. The main development risks are stability, dose uniformity, taste, viscosity, microbial control, and accurate administration.

Is biosimilar competition relevant to ELMIRON?

No. ELMIRON is a chemically manufactured oral drug product, not a biologic subject to the biosimilar pathway. Competition would arise through ANDA generics or, for differentiated products, a 505(b)(2) application.

References

1. U.S. Food and Drug Administration. (2023). ELMIRON (pentosan polysulfate sodium) prescribing information. Janssen Pharmaceuticals, Inc.

2. National Library of Medicine. (n.d.). DailyMed: ELMIRON- pentosan polysulfate sodium capsule. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

6. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/